Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

NCT04484337 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Cabotegravir sodium (Oral Lead In)
DRUG: Cabotegravir 400 mg/mL
DRUG: Cabotegravir 200 mg/mL
DRUG: Topical non-steroidal anti-inflammatory drug
DRUG: Topical steroid
DRUG: Placebo creams/gels
DRUG: Recombinant human hyaluronidase PH20 (rHuPH20)

Sponsor

ViiV Healthcare